NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$173.78 +1.57 (+0.91 %)
(As of 12/11/2018 06:12 AM ET)
Previous Close$172.21
Today's Range$167.63 - $174.3650
52-Week Range$139.80 - $194.92
Volume887,479 shs
Average Volume1.53 million shs
Market Capitalization$44.01 billion
P/E Ratio217.23
Dividend YieldN/A
Beta1.65
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
Previous Symbol
CUSIP92532F10
Phone617-341-6100

Debt

Debt-to-Equity Ratio0.01
Current Ratio3.71
Quick Ratio3.59

Price-To-Earnings

Trailing P/E Ratio217.23
Forward P/E Ratio68.15
P/E Growth1.71

Sales & Book Value

Annual Sales$2.49 billion
Price / Sales17.85
Cash Flow$1.0582 per share
Price / Cash Flow164.22
Book Value$8.08 per share
Price / Book21.51

Profitability

EPS (Most Recent Fiscal Year)$0.80
Net Income$263.48 million
Net Margins22.87%
Return on Equity22.92%
Return on Assets14.10%

Miscellaneous

Employees2,300
Outstanding Shares255,560,000
Market Cap$44.01 billion
OptionableOptionable

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals declared that its board has approved a stock buyback plan on Thursday, February 1st 2018, which authorizes the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings data on Wednesday, October, 24th. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.02 by $0.07. The pharmaceutical company had revenue of $784.54 million for the quarter, compared to the consensus estimate of $782.95 million. Vertex Pharmaceuticals had a return on equity of 22.92% and a net margin of 22.87%. During the same quarter last year, the firm posted $0.53 earnings per share. View Vertex Pharmaceuticals' Earnings History.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, January 30th 2019. View Earnings Estimates for Vertex Pharmaceuticals.

What price target have analysts set for VRTX?

22 brokerages have issued 12 month price objectives for Vertex Pharmaceuticals' shares. Their forecasts range from $175.00 to $220.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $201.6190 in the next year. This suggests a possible upside of 16.0% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals.

What is the consensus analysts' recommendation for Vertex Pharmaceuticals?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 2 hold ratings and 20 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals.

What are Wall Street analysts saying about Vertex Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ": $217 PT. Vertex released their first Ph3 top-line data for their cystic fibrosis triple regimen for homozygous and heterozygous patients. No change to our estimates. We already assumed 100% probability of success for the HetMin opportunity. Our 2025 cystic fibrosis peak estimate is $7.5B vs current 2018 estimated sales of $3B." (11/27/2018)
  • 2. According to Zacks Investment Research, "Vertex beat estimates for both earnings and sales in Q3. We are encouraged by Vertex’s dominance in the CF market. Consistent increase in eligible patient population for its two CF drugs, Kalydeco & Orkambi, is driving sales growth. Vertex’s third CF medicine, Symdeko, a tezacaftor/ivacaftor combo is off to a strong start with an EU launch scheduled in the fourth quarter. Symdeko has been a significant contributor to growth in 2018. Vertex’s CF pipeline is also accelerating rapidly. Studies on Vertex’s triple combination CF regimens are moving fast. The CF triple-pill regimes are crucial for long-term growth as these have the potential to treat up to 90% of CF patients. Meanwhile, Vertex’s non-CF pipeline, though early stage, looks interesting. The stock has outperformed the industry this year so far. However, competitive pressure is rising in the CF market with many companies developing triple combo CF drugs." (11/17/2018)

Has Vertex Pharmaceuticals been receiving favorable news coverage?

Media headlines about VRTX stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vertex Pharmaceuticals earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave media headlines about the pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Vertex Pharmaceuticals' key competitors?

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the folowing people:
  • Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 62)
  • Mr. Thomas Graney, CFO & Sr. VP (Age 53)
  • Mr. Ian F. Smith, Exec. VP & COO (Age 52)
  • Dr. David M. Altshuler, Chief Scientific Officer & Exec. VP of Global Research (Age 53)
  • Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 43)

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.80%), Vanguard Group Inc. (7.35%), FMR LLC (7.07%), Capital World Investors (3.01%), Jennison Associates LLC (2.43%) and Clearbridge Investments LLC (2.17%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Marshall Wace North America L.P., Clearbridge Investments LLC, TIAA CREF Investment Management LLC, Mitsubishi UFJ Trust & Banking Corp, Janus Henderson Group PLC, MERIAN GLOBAL INVESTORS UK Ltd and AXA. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Insider Buying and Selling for Vertex Pharmaceuticals.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Capital Research Global Investors, FMR LLC, Jennison Associates LLC, BlackRock Inc., Prudential Financial Inc., Panagora Asset Management Inc. and AQR Capital Management LLC. View Insider Buying and Selling for Vertex Pharmaceuticals.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $173.78.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $44.01 billion and generates $2.49 billion in revenue each year. The pharmaceutical company earns $263.48 million in net income (profit) each year or $0.80 on an earnings per share basis. Vertex Pharmaceuticals employs 2,300 workers across the globe.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is http://www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]


MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  1,233 (Vote Outperform)
Underperform Votes:  659 (Vote Underperform)
Total Votes:  1,892
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel